FIELD: medicine, chemical-pharmaceutical industry. SUBSTANCE: invention relates to a pharmaceutical composition for treatment of patients with hyperlipoproteinemia and atherosclerosis. Composition has an inhibitor of enzyme, HMG-CoA-reductase, for example, fluvastatin sodium, stabilized with an alkaline stabilizing agent from pH-associated degradation that is able to brought about pH value of an aqueous solution of dispersion of indicated composition to at least 8. Composition provides rapid and practically complete absorption of a drug by intestine. EFFECT: enhanced effectiveness of a composition proposed. 11 cl, 2 tbl
